NCT05603572View on ClinicalTrials.gov

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

PHASE1/PHASE2SuspendedINTERVENTIONAL

Enrollment

148

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Hepatocellular CarcinomaFibrolamellar Carcinoma

Interventions

DRUG

KAT-101

oral dosage form

DRUG

KAT-201

IT dosage form

Trial Locations (3)

Unknown

Kyungpook National University Hospital, Daegu

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Primocure Pharma

All Listed Sponsors

lead

Primocure Pharma

INDUSTRY